Interventional technology developer AngioDynamics has received expanded clearance from the U.S. Food and Drug Administration (FDA) for its OARtrac radiation dose monitoring system.
The FDA's decision allows the OARtrac system to be used with patient-specific, precalibrated peak skin dose sensors during cancer treatments to measure photon and electron radiation therapy as an adjunct to treatment planning. The feature is part of OARtrac's technology to help radiation oncologists and medical physicists monitor and validate radiation doses for a specific area of a patient's body.
OARtrac is also indicated for use with photon and electron energy when adhered to the skin or inserted into the rectum. Physicians can utilize a specially designed OARtrac endorectal balloon device to take measurements at the rectal wall during cancer treatment, AngioDynamics said.